E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
Elias Jabbour,Susan O'Brien,Hagop M. Kantarjian,Guillermo Garcia-Manero,Alessandra Ferrajoli,Farhad Ravandi,Maria E. Cabanillas,Deborah A. Thomas +7 more
TL;DR: Liposomal cytarabine was given for CNS prophylaxis to 31 patients with newly diagnosed ALL and five patients experienced serious unexpected neurotoxicity, including seizures, papilledema, cauda equina syndrome, and encephalitis.
Journal ArticleDOI
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver,Deborah A. Thomas,Farhad Ravandi,Jorge E. Cortes,Rebecca Garris,Elias Jabbour,Guillermo Garcia-Manero,Gautam Borthakur,Tapan M. Kadia,Michael Rytting,Marina Konopleva,Hagop M. Kantarjian,Susan O'Brien +12 more
TL;DR: HyperCVAD chemotherapy and imatinib is an effective regimen for Philadelphia- positive acute lymphoblastic leukemia and Transplant may not be indicated in all patients with Philadelphia-positive acute lymphblastic leukemia.
Journal ArticleDOI
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Farhad Ravandi,Susan O'Brien,Jorge E. Cortes,Deborah M. Thomas,Rebecca Garris,Stefan Faderl,Jan A. Burger,Michael Rytting,Alessandra Ferrajoli,William G. Wierda,Srdan Verstovsek,Richard E. Champlin,Partow Kebriaei,Deborah McCue,Xuelin Huang,Elias Jabbour,Guillermo Garcia-Manero,Zeev Estrov,Hagop M. Kantarjian +18 more
TL;DR: The long‐term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) is not well established.
Journal ArticleDOI
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour,Nicholas J. Short,Farhad Ravandi,Xuelin Huang,Naval Daver,Courtney D. DiNardo,Marina Konopleva,Naveen Pemmaraju,William G. Wierda,Guillermo Garcia-Manero,Koji Sasaki,Jorge E. Cortes,Rebecca Garris,Joseph D. Khoury,Jeffrey L. Jorgensen,Nitin Jain,Joie Alvarez,Susan O'Brien,Hagop M. Kantarjian +18 more
TL;DR: The combination of chemotherapy with ponatinib is effective in achieving long-term remission in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia, and this regimen could represent a new standard of care for this population.
Journal ArticleDOI
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Courtney D. DiNardo,Abhishek Maiti,Caitlin R. Rausch,Naveen Pemmaraju,Kiran Naqvi,Naval Daver,Tapan M. Kadia,Gautam Borthakur,Maro Ohanian,Yesid Alvarado,Ghayas C. Issa,Guillermo Montalban-Bravo,Nicholas J. Short,Musa Yilmaz,Prithviraj Bose,Elias Jabbour,Koichi Takahashi,Jan A. Burger,Guillermo Garcia-Manero,Nitin Jain,Steven M. Kornblau,Philip A. Thompson,Zeev Estrov,Lucia Masarova,Koji Sasaki,Srdan Verstovsek,Alessandra Ferrajoli,William Weirda,Sa A. Wang,Sergej Konoplev,Zhining Chen,Sherry Pierce,Jing Ning,Wei Qiao,Farhad Ravandi,Michael Andreeff,John S. Welch,Hagop M. Kantarjian,Marina Konopleva +38 more
TL;DR: It is hypothesized that venetoclax with 10-day decitabine could have improved activity in patients with newly diagnosed AML and those with relapsed or refractory AML, particularly in high-risk subgroups, as well as safety, overall survival, and duration of response.